Literature DB >> 33753862

Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition.

Jiani Yang1, Jun Ma1, Yue Jin1, Shanshan Cheng1, Shan Huang1, Nan Zhang1, Yu Wang2.   

Abstract

We aimed to determine the prognosis value of circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition in epithelial ovarian cancer (EOC) recurrence. We used CanPatrol CTC-enrichment technique to detect CTCs from blood samples and classify subpopulations into epithelial, mesenchymal, and hybrids. To construct nomogram, prognostic factors were selected by Cox regression analysis. Risk stratification was performed through Kaplan-Meier analysis among the training group (n = 114) and validation group (n = 38). By regression screening, both CTC counts (HR 1.187; 95% CI 1.098-1.752; p = 0.012) and M-CTC (HR 1.098; 95% CI 1.047-1.320; p = 0.009) were demonstrated as independent factors for recurrence. Other variables including pathological grade, FIGO stage, lymph node metastasis, ascites, and CA-125 were also selected (p < 0.005) to construct nomogram. The C-index of internal and external validation for nomogram was 0.913 and 0.874. We found significant predictive values for the nomogram with/without CTCs (AUC 0.8705 and 0.8097). Taking CTC counts and M-CTC into separation, the values were 0.8075 and 0.8262. Finally, survival curves of risk stratification based on CTC counts (p = 0.0241), M-CTC (p = 0.0107), and the nomogram (p = 0.0021) were drawn with significant differences. In conclusion, CTCs could serve as a novel factor for EOC prognosis. Nomogram model constructed by CTCs and other clinical parameters could predict EOC recurrence and perform risk stratification for clinical decision-making.Trial registration Chinese Clinical Trial Registry, ChiCTR-DDD-16009601, October 25, 2016.

Entities:  

Year:  2021        PMID: 33753862      PMCID: PMC7985206          DOI: 10.1038/s41598-021-86122-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  33 in total

Review 1.  Detection of Circulating Tumor Cells Using Microfluidics.

Authors:  Tiberiu A Burinaru; Marioara Avram; Andrei Avram; Cătălin Mărculescu; Bianca Ţîncu; Vasilica Ţucureanu; Alina Matei; Manuella Militaru
Journal:  ACS Comb Sci       Date:  2018-02-02       Impact factor: 3.784

Review 2.  Can we predict who lives long with ovarian cancer?

Authors:  Michael A Bookman
Journal:  Cancer       Date:  2019-12-15       Impact factor: 6.860

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.

Authors:  W Jeffrey Allard; Jeri Matera; M Craig Miller; Madeline Repollet; Mark C Connelly; Chandra Rao; Arjan G J Tibbe; Jonathan W Uhr; Leon W M M Terstappen
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

5.  Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer.

Authors:  Patricia L Judson; Melissa A Geller; Robin L Bliss; Matthew P Boente; Levi S Downs; Peter A Argenta; Linda F Carson
Journal:  Gynecol Oncol       Date:  2003-11       Impact factor: 5.482

6.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Authors:  Howard I Scher; Xiaoyu Jia; Johann S de Bono; Martin Fleisher; Kenneth J Pienta; Derek Raghavan; Glenn Heller
Journal:  Lancet Oncol       Date:  2009-02-11       Impact factor: 41.316

7.  Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).

Authors:  Linda R Duska; James J Java; David E Cohn; Robert A Burger
Journal:  Gynecol Oncol       Date:  2015-09-01       Impact factor: 5.482

8.  A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses.

Authors:  Giorgio Bogani; Elena Tagliabue; Mauro Signorelli; Antonino Ditto; Fabio Martinelli; Valentina Chiappa; Lavinia Mosca; Ilaria Sabatucci; Umberto Leone Roberti Maggiore; Domenica Lorusso; Francesco Raspagliesi
Journal:  J Gynecol Oncol       Date:  2018-02-23       Impact factor: 4.401

9.  Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.

Authors:  Xiao-Hui Zhao; Zai-Rui Wang; Chang-Long Chen; Ling Di; Zhuo-Fei Bi; Zhi-Hua Li; Yi-Min Liu
Journal:  World J Gastroenterol       Date:  2019-01-07       Impact factor: 5.742

10.  Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer.

Authors:  Se Ik Kim; Minsun Song; Suhyun Hwangbo; Sungyoung Lee; Untack Cho; Ju-Hyun Kim; Maria Lee; Hee Seung Kim; Hyun Hoon Chung; Dae-Shik Suh; Taesung Park; Yong-Sang Song
Journal:  Cancer Res Treat       Date:  2018-11-20       Impact factor: 4.679

View more
  8 in total

1.  Predictive Value of Circulating Tumor Cells in Prognosis of Stage III/IV Colorectal Cancer After Oxaliplatin-based First-line Chemotherapy.

Authors:  Jiazi Yu; John Zhang; Tao Peng; Zhenglei Fei; Liangbin Jin; Mian Yang
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

Review 2.  A meta-analysis of the prognostic value of circulating tumor cells in ovarian cancer.

Authors:  Xiaodan He; Shenjie Li; Yali Ni; Ming Jin; Xin Fu
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

3.  Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.

Authors:  Yang Song; Hui Qu
Journal:  BMC Cancer       Date:  2022-06-08       Impact factor: 4.638

4.  Development and External Validation of a Novel Model for Predicting Postsurgical Recurrence and Overall Survival After Cytoreductive R0 Resection of Epithelial Ovarian Cancer.

Authors:  Qiaqia Li; Yinghong Deng; Wei Wei; Fan Yang; An Lin; Desheng Yao; Xiaofeng Zhu; Jundong Li
Journal:  Front Oncol       Date:  2022-03-23       Impact factor: 6.244

Review 5.  Potential clinical utility of liquid biopsies in ovarian cancer.

Authors:  Jie Wei Zhu; Parsa Charkhchi; Mohammad R Akbari
Journal:  Mol Cancer       Date:  2022-05-11       Impact factor: 41.444

6.  Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.

Authors:  Xiao-Xiang Jie; Meng Zhang; Ming Du; Qing-Qing Cai; Qing Cong; Cong-Jian Xu; Xiao-Yan Zhang
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

7.  Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients.

Authors:  Du-Bois Asante; Michael Morici; Ganendra R K A Mohan; Emmanuel Acheampong; Isaac Spencer; Weitao Lin; Paula van Miert; Samantha Gibson; Aaron B Beasley; Melanie Ziman; Leslie Calapre; Tarek M Meniawy; Elin S Gray
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

8.  Artificial Intelligence Based on Blood Biomarkers Including CTCs Predicts Outcomes in Epithelial Ovarian Cancer: A Prospective Study.

Authors:  Jun Ma; Jiani Yang; Yue Jin; Shanshan Cheng; Shan Huang; Nan Zhang; Yu Wang
Journal:  Onco Targets Ther       Date:  2021-05-18       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.